Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Bristol-Myers Squibb
Hoffmann-La Roche
Astellas Pharma Inc
QuantumLeap Healthcare Collaborative
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
PMV Pharmaceuticals, Inc
Mayo Clinic
Dartmouth-Hitchcock Medical Center
Aminex Therapeutics, Inc.
Fudan University
Merck Sharp & Dohme LLC
NeoImmuneTech
MedSIR
National Institutes of Health Clinical Center (CC)
Alliance for Clinical Trials in Oncology
Merck Sharp & Dohme LLC
Genmab
Exelixis
Dana-Farber Cancer Institute
City of Hope Medical Center
Seagen Inc.
Bayer
Japanese Foundation for Cancer Research
Merck Sharp & Dohme LLC